First Wave BioPharma Performance
| FWBIDelisted Stock | USD 0.61 0.03 4.69% |
The firm shows a Beta (market volatility) of 0.35, which means possible diversification benefits within a given portfolio. As returns on the market increase, First Wave's returns are expected to increase less than the market. However, during the bear market, the loss of holding First Wave is expected to be smaller as well. First Wave BioPharma right now shows a risk of 0.0%. Please confirm First Wave BioPharma skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if First Wave BioPharma will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days First Wave BioPharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong fundamental drivers, First Wave is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 1.4 M |
First |
First Wave Relative Risk vs. Return Landscape
If you would invest 61.00 in First Wave BioPharma on August 25, 2024 and sell it today you would earn a total of 0.00 from holding First Wave BioPharma or generate 0.0% return on investment over 90 days. First Wave BioPharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than First, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
First Wave Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for First Wave's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as First Wave BioPharma, and traders can use it to determine the average amount a First Wave's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| FWBI |
Based on monthly moving average First Wave is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of First Wave by adding First Wave to a well-diversified portfolio.
First Wave Fundamentals Growth
First Stock prices reflect investors' perceptions of the future prospects and financial health of First Wave, and First Wave fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on First Stock performance.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | 72.56 M | |||
| Shares Outstanding | 2.03 M | |||
| Price To Book | 1.87 X | |||
| EBITDA | (15.74 M) | |||
| Cash And Equivalents | 1.16 M | |||
| Cash Per Share | 0.83 X | |||
| Total Debt | 826.84 K | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | 7.99 X | |||
| Cash Flow From Operations | (12.38 M) | |||
| Earnings Per Share | (47.88) X | |||
| Total Asset | 6.88 M | |||
| Retained Earnings | (184.33 M) | |||
About First Wave Performance
By evaluating First Wave's fundamental ratios, stakeholders can gain valuable insights into First Wave's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if First Wave has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if First Wave has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida. First Wave operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people.Things to note about First Wave BioPharma performance evaluation
Checking the ongoing alerts about First Wave for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for First Wave BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| First Wave BioPharma is now traded under the symbol ENTO. Please update your portfolios or report it if you believe this is an error. Report It! | |
| First Wave BioPharma is not yet fully synchronised with the market data | |
| First Wave BioPharma has some characteristics of a very speculative penny stock | |
| First Wave BioPharma has a very high chance of going through financial distress in the upcoming years | |
| First Wave BioPharma currently holds 826.84 K in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. First Wave BioPharma has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about First Wave's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| First Wave BioPharma currently holds about 1.16 M in cash with (12.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing First Wave's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether First Wave's stock is overvalued or undervalued compared to its peers.
- Examining First Wave's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating First Wave's management team can have a significant impact on its success or failure. Reviewing the track record and experience of First Wave's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of First Wave's stock. These opinions can provide insight into First Wave's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in First Stock
If you are still planning to invest in First Wave BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the First Wave's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |